Response of symptomatic brain metastases from HER-2 overexpressing breast cancer with T-DM1

J Neurooncol. 2016 Apr;127(2):401-3. doi: 10.1007/s11060-015-2045-1. Epub 2016 Jan 5.

Authors

C L Gorter de Vries¹, S C Linn², D Brandsma³

Affiliations

¹ Department of Neuro-oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
² Department of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
³ Department of Neuro-oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. [email protected].

PMID: 26732082
DOI: 10.1007/s11060-015-2045-1

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Ado-Trastuzumab Emtansine
Adult
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents / therapeutic use*
Brain Neoplasms / drug therapy*
Brain Neoplasms / metabolism
Brain Neoplasms / secondary
Breast Neoplasms / drug therapy*
Breast Neoplasms / metabolism
Breast Neoplasms / pathology
Female
Humans
Maytansine / analogs & derivatives*
Maytansine / therapeutic use
Prognosis
Receptor, ErbB-2 / metabolism*
Trastuzumab

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Maytansine
ERBB2 protein, human
Receptor, ErbB-2
Trastuzumab
Ado-Trastuzumab Emtansine